Effect of Starvation in Reversing Cancer Chemoresistance Based on Drug-Resistance Detection by Dextran Nanoparticles

References

• Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE. Gottesman, structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding. Nat Rev Cancer. 2018;18(7):452–464. doi:10.1038/s41568-018-0005-829643473
   PubMed Web of Science ®Google Scholar
• Leopoldo M, Nardulli P, Contino M, Leonetti F, Luurtsema G, Colabufo NA. An updated patent review on P-glycoprotein inhibitors (2011–2018). Expert Opin Ther Pat. 2019;29(6):455–461. doi:10.1080/13543776.2019.161827331079547
   PubMed Web of Science ®Google Scholar
• Naghizadeh S, Mansoori B, Mohammadi A, Sakhinia E, Baradaran B. Gene silencing strategies in cancer therapy: an update for drug resistance. Curr Med Chem. 2019;26(34):6282–6303.29611475
   PubMed Web of Science ®Google Scholar
• Takahashi S, Ito Y, Hatake K, Sugimoto Y. Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in cancer institute hospital. Breast Cancer. 2006;13(1):8–15.16518057
   PubMedGoogle Scholar
• Saneja A, Dubey RD, Alam N, Khare V, Gupta PN. Co-formulation of P-glycoprotein substrate and inhibitor in nanocarriers: an emerging strategy for cancer chemotherapy. Curr Cancer Drug Targets. 2014;14(5):419–433. doi:10.2174/156800961466614040711203424720364
   PubMed Web of Science ®Google Scholar
• Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309–318. doi:10.1007/s10585-018-9903-029799080
   PubMed Web of Science ®Google Scholar
• Miller DS, Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci. 2010;31(6):246–254. doi:10.1016/j.tips.2010.03.00320417575
   PubMed Web of Science ®Google Scholar
• Aller SG, Yu J, Ward A, et al. Structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323(5922):1718–1722. doi:10.1126/science.116875019325113
   PubMed Web of Science ®Google Scholar
• Wang CL, Wang FC, Zhang JG, Liu LS, Xu GX. Dou, fluorescent polysaccharide nanogels for the detection of tumor heterogeneity in drug-surviving cancer cells. Adv Biosyst. 2020;4(2):1900213. doi:10.1002/adbi.201900213
   Web of Science ®Google Scholar
• Biziota E, Mavroeidis L, Hatzimichael E, Pappas P. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett. 2017;400:243–251. doi:10.1016/j.canlet.2016.12.01828017892
   PubMed Web of Science ®Google Scholar
• Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, Longo V. Targeting cancer metabolism: dietary and pharmacologic interventions. Cancer Discov. 2016;6(12):1315–1333. doi:10.1158/2159-8290.CD-16-061527872127
   PubMed Web of Science ®Google Scholar
• Lee C, Raffaghello L, Longo VD. Starvation, detoxification, and multidrug resistance in cancer therapy. Drug Resist Update. 2012;15(1–2):114–122. doi:10.1016/j.drup.2012.01.004
   PubMed Web of Science ®Google Scholar
• Yu SJ, Chen ZW, Zeng X, Chen XS, Gu Z. Advances in nanomedicine for cancer starvation therapy. Theranostics. 2019;9(26):8026–8047. doi:10.7150/thno.3826131754379
   PubMed Web of Science ®Google Scholar
• Wang H, Dai TT, Li SL, et al. Scalable and cleavable polysaccharide nanocarriers for the delivery of chemotherapy drugs. Acta Biomater. 2018;72:206–216. doi:10.1016/j.actbio.2018.03.02429567106
   PubMed Web of Science ®Google Scholar
• Wang CL, Guan WC, Peng JL, Chen YT, Xu GX, Dou HJ. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors. Acta Biomater. 2020;103:247–258. doi:10.1016/j.actbio.2019.12.01531846802
   PubMed Web of Science ®Google Scholar
• Wang CL, Guan WC, Chen R, et al. Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential. Nano Res. 2020;13:3110–3122. doi:10.1007/s12274-020-2981-8
   Web of Science ®Google Scholar
• Wang CL, You JY, Gao MM, Zhang PP, Xu GX, Dou HJ. Bio-inspired gene carriers with low cytotoxicity constructed via the assembly of dextran nanogels and nano-coacervates. Nanomedicine. 2020;15:1285–1296. doi:10.2217/nnm-2020-0065
   Web of Science ®Google Scholar
• Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des. 2006;12(3):273–286. doi:10.2174/13816120677520196516454744
   PubMed Web of Science ®Google Scholar
• Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet. 2012;27(1):85–105. doi:10.2133/dmpk.DMPK-11-RV-09822123128
   PubMed Web of Science ®Google Scholar
• Sak K, Jarv J, Karelson M. ‘Strain effect’ descriptors for ATP and ADP derivatives with modified phosphate groups. Comput Chem. 2002;26(4):341–346.12139416
   PubMedGoogle Scholar
• Kato Y, Maeda T, Suzuki A, Baba Y. Cancer metabolism: new insights into classic characteristics. Jpn Dent Sci Rev. 2018;54(1):8–21. doi:10.1016/j.jdsr.2017.08.00329628997
   PubMed Web of Science ®Google Scholar
• Meng Y, Xu X, Luan HY, et al. The progress and development of GLUT1 inhibitors targeting cancer energy metabolism. Future Med Chem. 2019;11(17):2333–2352. doi:10.4155/fmc-2019-005231581916
   PubMed Web of Science ®Google Scholar
• Garcia SN, Guedes RC, Marques MM. Unlocking the potential of HK2 in cancer metabolism and therapeutics. Curr Med Chem. 2019;26(41):7285–7322.30543165
   PubMed Web of Science ®Google Scholar
• Li YH, Li XF, Liu JT, et al. PKM2, a potential target for regulating cancer. Gene. 2018;668:48–53. doi:10.1016/j.gene.2018.05.03829775756
   PubMed Web of Science ®Google Scholar
• Thongon N, Zucal C, D’Agostino VG, et al. Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA. Cancer Metab. 2018;6:1. doi:10.1186/s40170-018-0174-729541451
   PubMed Web of Science ®Google Scholar
• Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–364. doi:10.1038/nature1262724048068
   PubMed Web of Science ®Google Scholar
• Maishi N, Annan DA, Kikuchi H, Hida Y, Hida K. Tumor endothelial heterogeneity in cancer progression. Cancers. 2019;11(10):1511. doi:10.3390/cancers11101511
   PubMed Web of Science ®Google Scholar
• Jeon JH, Kim DK, Shin Y, et al. Migration and invasion of drug-resistant lung adenocarcinoma cells are dependent on mitochondrial activity. Exp Mol Med. 2016;48:e277. doi:10.1038/emm.2016.12927932791
   PubMed Web of Science ®Google Scholar
• Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I. The hypoxic tumour microenvironment. Oncogenesis. 2018;7:10. doi:10.1038/s41389-017-0011-929362402
   PubMed Web of Science ®Google Scholar
• Tirandaz H, Mohammadi E. Efficient tumor targeting by anaerobic butyrate-producing bacteria. Med Hypotheses. 2013;80(5):675–678. doi:10.1016/j.mehy.2013.01.02423410499
   PubMed Web of Science ®Google Scholar
• Zheng DW, Chen Y, Li ZH, et al. Optically-controlled bacterial metabolite for cancer therapy. Nat Commun. 2018;9:1680. doi:10.1038/s41467-018-03233-929700283
   PubMed Web of Science ®Google Scholar
• Wang FC, Zhang LY, Liu J, Zhang JG, Xu GX. Highly expressed STAT1 contributes to the suppression of sternness properties in human paclitaxel-resistant ovarian cancer cells. Aging-US. 2020;12(11):11042–11060. doi:10.18632/aging.103317
   Web of Science ®Google Scholar